Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
The U.S. FDA issued a Form 483 with five observations
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Subscribe To Our Newsletter & Stay Updated